Cyclo Therapeutics, Inc.
CYTHNASDAQHealthcare
$0.72
+$0.00(+0.00%)
Market Cap$23589778
P/E Ratio—
52W High$1.6199
52W Low$0.55
Cyclo Therapeutics, Inc. (CYTH) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CYTH · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.08M | $1.38M | $1.59M | $0.90M | $1.01M |
| Cost of Revenue | $0.10M | $0.14M | $0.16M | $0.07M | $0.08M |
| Gross Profit | $0.98M | $1.24M | $1.43M | $0.84M | $0.93M |
| Gross Margin %(computed) | 90.85% | 89.90% | 90.16% | 92.65% | 92.50% |
| Operating Expenses | |||||
| R&D Expenses | $14.18M | $9.00M | $9.15M | $6.10M | $4.87M |
| G&A Expenses | $5.66M | $7.81M | $6.50M | $3.68M | $3.43M |
| Total Operating Expenses | $21.04M | $16.85M | $15.70M | $9.80M | $8.32M |
| Operating Income | ($20.05M) | ($15.61M) | ($14.27M) | ($8.96M) | ($7.39M) |
| Operating Margin %(computed) | — | — | -899.77% | -991.85% | -733.80% |
| Interest Income | $0.00M | $0.01M | $0.00M | $0.02M | $0.01M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($20.06M) | ($15.45M) | ($14.29M) | ($8.94M) | ($7.53M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($20.06M) | ($15.28M) | ($14.31M) | ($8.92M) | ($7.67M) |
| Net Margin %(computed) | — | — | -902.10% | -987.75% | -761.94% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.23 | $-1.81 | $-2.25 | $-5.58 | $-7.09 |
| Wtd Avg Shares | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M |
| EBITDA | ($20.03M) | ($15.60M) | ($14.27M) | ($8.95M) | ($7.39M) |
| EBITDA Margin %(computed) | — | — | -899.88% | -990.58% | -733.23% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Cyclo Therapeutics, Inc. data
About Cyclo Therapeutics, Inc. (CYTH) Income Statement
Cyclo Therapeutics, Inc. (CYTH) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, CYTH reported revenue of $0.00B, gross profit of $0.00B (gross margin 90.85%), and net income of ($0.02B) — a net profit margin of -1863.36%.
Frequently asked questions
CYTH · 4 questionsCyclo Therapeutics, Inc. (CYTH) reported revenue of $0.00B for 2023, down 21.8% year-over-year.
CYTH revenueCYTH salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09